Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Douglass W. Forsha"'
Autor:
Janice Drew, Adelaide A. Hebert, Lawrence Green, Dee Anna Glaser, David M. Pariser, William Philip Werschler, Douglass W. Forsha, Ramanan Gopalan
Publikováno v:
Pediatric Dermatology
Objectives Hyperhidrosis in pediatric patients has been understudied. Post hoc analyses of two phase 3 randomized, vehicle‐controlled, 4‐week trials (ATMOS‐1 [NCT02530281] and ATMOS‐2 [NCT02530294]) were performed to assess efficacy and safet
Autor:
Amy S. Paller, Lee T. Zane, Mark Boguniewicz, William C. Rees, Lawrence F. Eichenfield, Mark Lebwohl, Adelaide A. Hebert, Faad, Robert S. Call, Wynnis L. Tom, Douglass W. Forsha
Publikováno v:
Section on Advances in Therapeutics and Technology Program.
Background: Atopic dermatitis (AD) is an inflammatory skin disease affecting children and adults, and up to 90% of patients present with mild to moderate AD. Crisaborole Topical Ointment, 2% (Anacor Pharmaceuticals, Palo Alto, CA), is an investigatio
Autor:
Eduardo Tschen, Mary Spellman, Adelaide A. Hebert, Robert S. Call, Lawrence F. Eichenfield, Douglass W. Forsha, Linda Stein Gold, Joseph F. Fowler, Merrie Van Syoc, Lee T. Zane
Publikováno v:
Journal of the American Academy of Dermatology. 77(4)
Background Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease. Objective To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N =
Autor:
Douglass W. Forsha, Ramanan Gopalan, William Philip Werschler, Lawrence Green, Janice Drew, David M. Pariser, Adelaide A Hebert, Dee Anna Glaser
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 2:S68
not available. Disclosures: Study sponsored by Dermira Inc. Copyright 2018 SKIN
Autor:
Amy S. Paller, Gil Yosipovitch, Wynnis L. Tom, Mark Lebwohl, Mark Boguniewicz, Robert S. Call, Lawrence F. Eichenfield, Douglass W. Forsha, William C. Rees, Eric L. Simpson, Linda F. Stein Gold, Andrea L. Zaenglein, Anna M. Tallman, Bill Tan, Adelaide A. Hebert
Publikováno v:
Pediatrics. 142:815-815
Autor:
Lee T. Zane, Adelaide A. Hebert, Linda Stein Gold, Lawrence F. Eichenfield, Merrie Van Syoc, Douglass W. Forsha, Mary Spellman, Faad, Robert S. Call, Joseph F. Fowler, Eduardo Tschen
Publikováno v:
Pediatrics. 141:271-271
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting children and adults. Approximately 85% of patients develop AD by age 5 years, and long-term topical treatment is often required. Unfortunately, topical therapies are
Autor:
Lawrence Eichenfield, M. Van Syoc, Douglass W. Forsha, Mary Spellman, Eduardo Tschen, Joseph F. Fowler, Lee T. Zane, L. Stein Gold, Robert S. Call, Adelaide A. Hebert
Publikováno v:
Annals of Allergy, Asthma & Immunology. 117:S21
Autor:
Linda Stein Gold, Robert S. Call, Douglass W. Forsha, Matilda H. Hughes, Wynnis L. Tom, Adelaide A. Hebert, Lee T. Zane, Amy S. Paller, Eric L. Simpson, Andrea L. Zaenglein, Mary Spellman, Lawrence F. Eichenfield, William C. Rees, Mark Lebwohl, Robin L. Blumenthal, Mark Boguniewicz
Publikováno v:
Journal of the American Academy of Dermatology. 75:494-503.e6
BackgroundAdditional topical treatments for atopic dermatitis (AD) are needed that provide relief while minimizing risks.ObjectiveWe sought to assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, in two phase III A
Autor:
Lawrence F. Eichenfield, Adelaide A. Hebert, W.C. Rees, Douglass W. Forsha, Lee T. Zane, Mary Spellman, Wynnis L. Tom, Amy S. Paller, R.S. Call
Publikováno v:
Journal of Investigative Dermatology. 136:S166
Autor:
Lee Thomas Zane, Amy S. Paller, Wynnis L. Tom, Mark G. Lebwohl, Robin L. Blumenthal, Mark Boguniewicz, Robert S. Call, Lawrence F. Eichenfield, Douglass W. Forsha, William C. Rees, Eric L. Simpson, Linda F. Stein Gold, Andrea L. Zaenglein, Adelaide A. Hebert
Publikováno v:
The Journal of Immunology. 196:191.26-191.26
Up to 90% of children and adults with atopic dermatitis (AD), a chronic inflammatory skin disease, present with mild-to-moderate disease. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhi